Infectious Disease Division; Memorial Hospital of RI; Providence, RI USA; The Alpert Medical School of Brown University; Providence, RI USA.
Virulence. 2014 Jan 1;5(1):206-12. doi: 10.4161/viru.26210. Epub 2013 Aug 27.
Multi-antibiotic drug-resistant (MDR) gram-negative bacilli are becoming a major threat to the standard care of septic patients. Empiric antimicrobial drug regimens to cover likely bacterial pathogens have to be altered in keeping with the spread of MDR pathogens in the health care setting and in the community. Reliable antibiotics for broad spectrum coverage for sepsis such as extended spectrum β-lactam antibiotics, carbapenems, and fluoroquinolones can no longer be counted upon to provide activity against a range of common, virulent pathogens that cause sepsis. In some regions of Asia, South America, and Eastern Europe in particular, MDR pathogens have become a major concern, necessitating the use of potentially toxic and costly antibiotic combinations as initial antibiotic therapy for septic shock. In this brief review, we will focus on the emergence of MDR gram-negative pathogens, resistance mechanisms, and suggest some management and prevention strategies against MDR pathogens.
多药耐药(MDR)革兰氏阴性杆菌对脓毒症患者的标准治疗构成了重大威胁。为了应对医疗机构和社区中 MDR 病原体的传播,必须根据可能的细菌病原体改变经验性抗菌药物治疗方案。对于脓毒症的广谱覆盖,如扩展谱β-内酰胺类抗生素、碳青霉烯类和氟喹诺酮类等可靠抗生素,已不能指望对引起脓毒症的一系列常见、毒力强的病原体具有活性。在亚洲、南美洲和东欧的一些地区,MDR 病原体已成为一个主要关注点,需要使用潜在有毒和昂贵的抗生素组合作为脓毒性休克的初始抗生素治疗。在这篇简要综述中,我们将重点关注 MDR 革兰氏阴性病原体的出现、耐药机制,并提出一些针对 MDR 病原体的管理和预防策略。